NCT01924065View on ClinicalTrials.gov

Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation

PHASE3CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

August 31, 2017

Study Completion Date

October 29, 2024

Conditions
Atrial FibrillationCardioversionCerebrovascular Stroke
Interventions
PROCEDURE

Cardioversion

Electrical cardioversion

DRUG

Oral Anticoagulant

warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage

Trial Locations (1)

32260

Suleyman Demirel University, Isparta

All Listed Sponsors
lead

Suleyman Demirel University

OTHER

NCT01924065 - Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation | Biotech Hunter | Biotech Hunter